The methods of disease diagnosis have certainly been revolutionized by numerous technologies over the past 20 years. In Ophthalmology, this progression has lagged behind other sectors, while blinding eye diseases continue to grow at a staggering pace because of the baby-boomer generation. Ocular Proteomics (OPL) aims to change this by using their discovery of proteins that are differentially activated in blinding diseases.
The Diagnostic Vitreous Proteome is a molecular based tool to provide Ophthalmologists with a better understanding about which treatments may work best, and conversely which ones that won't work at all! The benefits of this are two fold: administering effective treatment to patients at the earliest possible time saves their long term vision, & costs savings from extended periods of non-effective treatments.
Identifying an individual patient's "protein fingerprint" is the future bedrock of disease treatment, much like HER2 is in breast cancer today.